Exelixis (EXEL) Change in Account Payables (2016 - 2026)
Exelixis' (EXEL) quarterly Change in Account Payables came in at -$17.9 million in Q2 2026, down 310.53% year-on-year from $8.5 million in Q2 2025, and down 38.74% quarter-over-quarter from -$12.9 million in Q1 2026.
Exelixis (EXEL) Change in Account Payables (2016 - 2026) Analysis & Trends
Exelixis' Change in Account Payables history runs 11 years deep, the most recent figure standing at -$17.9 million for Q2 2026.
- On a quarterly basis, Change in Account Payables fell 310.53% year-over-year to -$17.9 million in Q2 2026; TTM through Apr 2026 was -$76.6 million, a 466.94% decrease from a year earlier, with the FY2026 full-year figure at -$50.2 million, down 129.15% from the prior year.
- Change in Account Payables fell to -$17.9 million in Q2 2026 per EXEL's latest filing, from -$12.9 million in the prior quarter.
- Across five years, Change in Account Payables topped out at $43.6 million in Q4 2023 and bottomed at -$63.5 million in Q3 2025.
- The 5-year median for Change in Account Payables is $2.2 million (2025), against an average of -$968823.5.
- Biggest YoY gain for Change in Account Payables was 3481.14% in 2024; the steepest drop was 8332.45% in 2024.
- Year by year, Change in Account Payables stood at $19.8 million in 2022, then jumped by 120.68% to $43.6 million in 2023, then slumped by 39.52% to $26.4 million in 2024, then sank by 32.73% to $17.8 million in 2025, then sank by 200.8% to -$17.9 million in 2026.
- Per Business Quant, the three latest EXEL Change in Account Payables figures stand at -$17.9 million (Q2 2026), -$12.9 million (Q1 2026), and $17.8 million (Q4 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Account Payables (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | -42.19 Mn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | -1.52 Mn |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 35.60 Mn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | - |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | 16.86 Mn |
| 10 | Exelixis | 14.38 Bn | 13.60 Bn | 590.86 Mn | -17.90 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Apr 3, 2026 | -17.90 Mn |
| Apr 3, 2026 | -17.90 Mn |
| Jan 2, 2026 | -12.90 Mn |
| Jan 2, 2026 | -12.90 Mn |
| Oct 3, 2025 | 17.76 Mn |
| Oct 3, 2025 | 17.76 Mn |
| Jul 4, 2025 | -63.51 Mn |
| Jul 4, 2025 | -63.51 Mn |
| Apr 4, 2025 | 8.50 Mn |
| Apr 4, 2025 | 8.50 Mn |
| Jan 3, 2025 | 2.24 Mn |
| Jan 3, 2025 | 2.24 Mn |
| Sep 27, 2024 | 26.39 Mn |
| Sep 27, 2024 | 26.39 Mn |
| Jun 28, 2024 | -16.28 Mn |
| Jun 28, 2024 | -16.28 Mn |
| Mar 29, 2024 | -34.25 Mn |
| Mar 29, 2024 | -34.25 Mn |
| Dec 29, 2023 | 43.64 Mn |
| Dec 29, 2023 | 43.64 Mn |